Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 4 July 2025, 18:59 HKT/SGT
Share:
Everest Medicines Unveils Breakthroughs in AI+mRNA Platform, Reinforces Global Leadership in Next-Gen mRNA Innovation

HONG KONG, July 4, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) recently unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day held in Shanghai. The event showcased the company’s progress in building a fully integrated and independently operated mRNA platform and highlighted significant breakthroughs across several pipeline programs in cancer and autoimmune diseases.

These achievements not only mark the accelerated implementation of Everest Medicines’ “dual-engine” strategy, but also reflect the company’s evolution from an initial license-in model to a balanced approach that integrates in-house discovery with global partnerships and in-licensing—focusing on high-value therapeutic areas and the development of first-in-class or best-in-class assets.

Everest is among a select group of biopharmaceutical companies worldwide with full in-house capabilities across the entire mRNA development chain. The company has successfully localized and industrialized its mRNA platform, building a fully integrated and scalable end-to-end system that spans AI-powered antigen design, mRNA sequence optimization, proprietary LNP delivery technologies, and GMP-compliant manufacturing.

Everest has developed an advanced LNP platform with over 500 proprietary lipid formulations, underpinned by a strong patent portfolio focused on ionizable and stealth lipids. This platform supports flexible delivery for a wide range of modalities, including vaccines and in vivo CAR-T therapies. Preclinical data have demonstrated the platform’s high efficacy, safety, and tunable delivery across hepatic and extrahepatic tissues, enabling both passive and active targeting strategies. The platform also boasts clinical validation through Everest’s COVID-19 vaccine candidate, PTX-COVID19-B, which in a global Phase 2 head-to-head trial showed comparable immunogenicity and tolerability to Pfizer/BioNTech’s Comirnaty®.

At the R&D Day, Everest unveiled development updates on three key assets powered by its AI+mRNA platform. EVM16 is a novel personalized mRNA cancer vaccine developed in-house using the company’s third-generation AI-based neoantigen prediction algorithm, EVER-NEO-1. This algorithm identifies patient-specific mutations and encodes them into customized mRNA sequences, which are delivered via LNPs to stimulate targeted T-cell responses. Preclinical studies in melanoma models demonstrated strong antitumor efficacy and synergy with PD-1 inhibitors. In March 2025, the first patient was dosed in an investigator-initiated trial (IIT), with early results showing robust, mutation-specific T-cell responses even at low initial doses—highlighting both the vaccine’s strong immunogenicity and the reliability of Everest’s proprietary EVER-NEO-1 AI algorithm.

EVM14 is an off-the-shelf therapeutic mRNA vaccine targeting five tumor-associated antigens, applicable to multiple squamous carcinomas including non-small cell lung cancer and head and neck cancer. Preclinical research indicates EVM14 may enhance immune memory and reduce tumor recurrence. The program has received FDA Investigational New Drug (IND) clearance and is progressing toward IND submission in China. The first clinical batch of EVM14 were released from Everest’s Jiashan manufacturing facility in June 2025 and are expected to arrive at U.S. clinical trial centers by mid-August.

For its in vivo CAR-T program, Everest is leveraging a proprietary targeted lipid nanoparticle (tLNP) delivery system, which enables the in vivo generation of CAR-T cells without the need for lymphodepletion. In preclinical studies conducted in both humanized mouse models and non-human primates (NHPs), the approach demonstrated high T-cell transduction efficiency, robust CAR expression, and effective B-cell clearance. This therapy offers a scalable, off-the-shelf alternative to conventional CAR-T treatments, with controllable dosing and an improved safety profile—positioning it as a potential game-changer in both oncology and autoimmune indications.

Everest Medicines’ AI+mRNA platform is advancing the development of a broad pipeline of therapeutic candidates, with strong potential demonstrated in cancer and autoimmune diseases. These advancements further demonstrate the effectiveness of Everest’s dual-engine strategy, underscoring the company’s ability to execute on its vision of combining in-house innovation with strategic external partnerships.

According to Everest Medicines CEO Rogers Yongqing Luo, personalized mRNA vaccines and in vivo CAR-T therapies are emerging as promising solutions to address critical challenges in cancer treatment, such as poor immune memory and high recurrence rates. He noted that mRNA technology—characterized by rapid design, scalable production, and cross-indication versatility—is reshaping the landscape of precision medicine. Everest plans to continue leveraging its end-to-end mRNA platform to advance key pipeline programs, including cancer vaccines and mRNA-based cell therapies, while expanding opportunities for application and global collaboration.

Rogers also revealed that the company has initiated discussions with several top 20 global pharmaceutical companies and is leveraging international resources to accelerate the global development of its innovative assets.

As Everest continues to advance both clinically and technologically, the integration of its mRNA platform with its core assets in nephrology and immunology is expected to drive a robust three-pillar growth strategy—anchored in platform innovation, differentiated products, and targeted market expansion. Backed by strong momentum across three globally competitive assets and a clinically validated, IP-rich platform, Everest is well positioned to redefine its long-term valuation narrative and emerge as a global leader in next-generation therapeutics.




Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Hong Kong Book Fair, Sports and Leisure Expo and World of Snacks to reopen earlier at 9am tomorrow with extended evening hours  
July 20, 2025 17:53 HKT/SGT
Typhoon special arrangements for Hong Kong Book Fair, Hong Kong Sports and Leisure Expo and World of Snacks  
July 19, 2025 21:09 HKT/SGT
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis  
July 18, 2025 21:00 HKT/SGT
Virturo Broker Launches Enhanced AI-Powered Trading Suite at London Investor Summit  
July 18, 2025 17:00 HKT/SGT
Doubleview Gold Corp Provides Comprehensive Update on Its Flagship Project - the Polymetallic Hat Deposit  
July 18, 2025 14:09 HKT/SGT
Honda Koraidon First Showrun during Suzuka 8 Hours
  
Friday, July 18, 2025 10:06:00 AM
SJC2 optical submarine cable in operation  
Friday, July 18, 2025 8:36:00 AM
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability  
July 18, 2025 00:05 HKT/SGT
Belgian Aircrew Completes MQ-9B Training  
July 18, 2025 00:05 HKT/SGT
A New Transatlantic Partnership for European CCA  
July 18, 2025 00:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: